Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Sugino, S., & Janicki, P. K. (2015, January 1). Pharmacogenetics of chemotherapy-induced nausea and vomiting. Pharmacogenomics. Future Medicine Ltd. https://doi.org/10.2217/pgs.14.168